TY - JOUR
T1 - The effect of oral administration of Lactobacillus GG on antibiotic-associated gastrointestinal side-effects during Helicobacter pylori eradication therapy
AU - Armuzzi, A.
AU - Cremonini, F.
AU - Bartolozzi, F.
AU - Canducci, F.
AU - Candelli, M.
AU - Ojetti, V.
AU - Cammarota, G.
AU - Anti, M.
AU - De Lorenzo, A.
AU - Pola, P.
AU - Gasbarrini, G.
AU - Gasbarrini, A.
PY - 2001
Y1 - 2001
N2 - Background: One-week triple therapy is currently considered the golden standard against Helicobacter pylori. However, gastrointestinal side-effects are among the major pitfalls in such regimens. Probiotic supplementation might help to prevent or reduce such drug-related manifestations. Aim: To determine whether adding the probiotic Lactobacillus GG to an anti-H. pylori regimen could help to prevent or minimize the gastrointestinal side-effects burden. Methods: Sixty healthy asymptomatic subjects screened positive for H. pylori infection were randomized to 1 week rabeprazole (20 mg b.d.), clarithromycin (500 mg b.d.), tinidazole (500 b.d.) and the probiotic Lactobacillus GG for 14 days or to the same regimen with a placebo preparation. Patients completed validated questionnaires during the week of treatment and during the following 3 weeks, to determine the type and severity of side-effects and an overall judgement of tolerability. Results: Diarrhoea, nausea and taste disturbance were significantly reduced in the Lactobacillus GG supplemented group (relative risk = 0.1, 95% CI: 0.1-0.9; relative risk = 0.3, 95% CI: 0.1-0.9; relative risk = 0.5, 95% CI: 0.2-0.9, respectively). An overall assessment of treatment tolerability showed a significant difference in favour of the Lactobacillus GG supplemented group (P = 0.04). Conclusions: Lactobacillus GG supplementation showed a positive impact on H. pylori therapy-related side-effects and on overall treatment tolerability.
AB - Background: One-week triple therapy is currently considered the golden standard against Helicobacter pylori. However, gastrointestinal side-effects are among the major pitfalls in such regimens. Probiotic supplementation might help to prevent or reduce such drug-related manifestations. Aim: To determine whether adding the probiotic Lactobacillus GG to an anti-H. pylori regimen could help to prevent or minimize the gastrointestinal side-effects burden. Methods: Sixty healthy asymptomatic subjects screened positive for H. pylori infection were randomized to 1 week rabeprazole (20 mg b.d.), clarithromycin (500 mg b.d.), tinidazole (500 b.d.) and the probiotic Lactobacillus GG for 14 days or to the same regimen with a placebo preparation. Patients completed validated questionnaires during the week of treatment and during the following 3 weeks, to determine the type and severity of side-effects and an overall judgement of tolerability. Results: Diarrhoea, nausea and taste disturbance were significantly reduced in the Lactobacillus GG supplemented group (relative risk = 0.1, 95% CI: 0.1-0.9; relative risk = 0.3, 95% CI: 0.1-0.9; relative risk = 0.5, 95% CI: 0.2-0.9, respectively). An overall assessment of treatment tolerability showed a significant difference in favour of the Lactobacillus GG supplemented group (P = 0.04). Conclusions: Lactobacillus GG supplementation showed a positive impact on H. pylori therapy-related side-effects and on overall treatment tolerability.
UR - http://www.scopus.com/inward/record.url?scp=0035129632&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0035129632&partnerID=8YFLogxK
U2 - 10.1046/j.1365-2036.2001.00923.x
DO - 10.1046/j.1365-2036.2001.00923.x
M3 - Article
C2 - 11148433
AN - SCOPUS:0035129632
VL - 15
SP - 163
EP - 169
JO - Alimentary Pharmacology and Therapeutics
JF - Alimentary Pharmacology and Therapeutics
SN - 0269-2813
IS - 2
ER -